Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment

• Published in: Biomaterials research Vol. 28; p. 0023
• Main Authors: Li, Mengmeng, Chen, Fenglei, Yang, Qian, Tang, Qinglai, Xiao, Zian, Tong, Xinying, Zhang, Ying, Lei, Lanjie, Li, Shisheng
• Format: Journal Article
• Language: English
• Published: United States AAAS 2024; 한국생체재료학회
• Subjects: Review; 의공학
• ISSN: 1226-4601; 2055-7124; 2055-7124
• DOI: 10.34133/bmr.0023

CRISPR/Cas9 gene editing technology is characterized by high specificity and efficiency, and has been applied to the treatment of human diseases, especially tumors involving multiple genetic modifications. However, the clinical application of CRISPR/Cas9 still faces some major challenges, the most urgent of which is the development of optimized delivery vectors. Biomaterials are currently the best choice for use in CRISPR/Cas9 delivery vectors owing to their tunability, biocompatibility, and efficiency. As research on biomaterial vectors continues to progress, hope for the application of the CRISPR/Cas9 system for clinical oncology therapy builds. In this review, we first detail the CRISPR/Cas9 system and its potential applications in tumor therapy. Then, we introduce the different delivery forms and compare the physical, viral, and non-viral vectors. In addition, we analyze the characteristics of different types of biomaterial vectors. We further review recent research progress in the use of biomaterials as vectors for CRISPR/Cas9 delivery to treat specific tumors. Finally, we summarize the shortcomings and prospects of biomaterial-based CRISPR/Cas9 delivery systems.